Iovance biotherapeutics appoints dan kirby as chief commercial officer

San carlos, calif., feb. 10, 2025 (globe newswire) -- iovance biotherapeutics, inc. (nasdaq: iova), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (til) therapies for patients with cancer, today announced that dan kirby will join the company's executive leadership team in the newly created role of chief commercial officer, effective today.
KEX Ratings Summary
KEX Quant Ranking